News
- InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride. 2022/08/29
- Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S. 2022/03/29
- First-Patient-In (FPI) of N11005-Oral Insulin Investigator-Initiated-Trial (IIT). 2022/02/10
- InnoPharmax have entered supply contract with Astellas in Germany for the Bendamustine. 2022/01/18
- InnoPharmax is invited to participate in the online corporate presentation held by Yuan Fu Securities.. 2021/12/23
